9 Meters Biopharma, Inc.
Limited financial coverage for NMTRQ.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
Operating as a clinical-stage biopharmaceutical firm, 9 Meters Biopharma, Inc. specialized in creating therapies for individuals in North America afflicted by rare digestive illnesses, various gastrointestinal disorders lacking effective treatments, and other debilitating conditions. Its primary therapeutic candidate was Vurolenatide, a long-acting injectable glucagon-like peptide-1, which had advanced to Phase 3 clinical trials for the management of short bowel syndrome.
- CEO
- Peter H. R. Green
- IPO
- 2016
- Employees
- 10
- HQ
- Raleigh, NC, US
Get TickerSpark's AI analysis on NMTRQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 8.28
- RSI (14)
- 53
- Avg Volume
- 170
No earnings-call transcripts are available for NMTRQ yet.
- Free Float
- 98.3%
- Shares Outstanding
- 14.46M
- Float Shares
- 14.22M
Our NMTRQ coverage
Recent articles, reports, and earnings notes.
No research on NMTRQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NMTRQ report →